170 related articles for article (PubMed ID: 36090755)
1. Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations.
Dudhal S; Mekzine L; Prudhon B; Soocheta K; Cadot B; Mamchaoui K; Trochet D; Bitoun M
Mol Ther Nucleic Acids; 2022 Sep; 29():733-748. PubMed ID: 36090755
[TBL] [Abstract][Full Text] [Related]
2. Different in vivo impacts of dynamin 2 mutations implicated in Charcot-Marie-Tooth neuropathy or centronuclear myopathy.
Massana Muñoz X; Buono S; Koebel P; Laporte J; Cowling BS
Hum Mol Genet; 2019 Dec; 28(24):4067-4077. PubMed ID: 31628461
[TBL] [Abstract][Full Text] [Related]
3. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.
Trochet D; Prudhon B; Beuvin M; Peccate C; Lorain S; Julien L; Benkhelifa-Ziyyat S; Rabai A; Mamchaoui K; Ferry A; Laporte J; Guicheney P; Vassilopoulos S; Bitoun M
EMBO Mol Med; 2018 Feb; 10(2):239-253. PubMed ID: 29246969
[TBL] [Abstract][Full Text] [Related]
4. Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes.
Rabai A; Reisser L; Reina-San-Martin B; Mamchaoui K; Cowling BS; Nicot AS; Laporte J
Mol Ther Nucleic Acids; 2019 Jun; 16():246-256. PubMed ID: 30925452
[TBL] [Abstract][Full Text] [Related]
5. Dynamin 2 mutations in Charcot-Marie-Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination.
Sidiropoulos PN; Miehe M; Bock T; Tinelli E; Oertli CI; Kuner R; Meijer D; Wollscheid B; Niemann A; Suter U
Brain; 2012 May; 135(Pt 5):1395-411. PubMed ID: 22451505
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-Function Properties of a Dynamin 2 Mutant Implicated in Charcot-Marie-Tooth Disease.
Tassin TC; Barylko B; Hedde PN; Chen Y; Binns DD; James NG; Mueller JD; Jameson DM; Taussig R; Albanesi JP
Front Cell Neurosci; 2021; 15():745940. PubMed ID: 34744632
[TBL] [Abstract][Full Text] [Related]
7. DNM2 levels normalization improves muscle phenotypes of a novel mouse model for moderate centronuclear myopathy.
de Carvalho Neves J; Moschovaki-Filippidou F; Böhm J; Laporte J
Mol Ther Nucleic Acids; 2023 Sep; 33():321-334. PubMed ID: 37547294
[TBL] [Abstract][Full Text] [Related]
8. Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy.
Trochet D; Prudhon B; Mekzine L; Lemaitre M; Beuvin M; Julien L; Benkhelifa-Ziyyat S; Bui MT; Romero N; Bitoun M
Mol Ther Nucleic Acids; 2022 Mar; 27():1179-1190. PubMed ID: 35282416
[TBL] [Abstract][Full Text] [Related]
9. Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease.
Zhao M; Maani N; Dowling JJ
Neurotherapeutics; 2018 Oct; 15(4):966-975. PubMed ID: 30426359
[TBL] [Abstract][Full Text] [Related]
10. Reducing dynamin 2 (DNM2) rescues
Buono S; Ross JA; Tasfaout H; Levy Y; Kretz C; Tayefeh L; Matson J; Guo S; Kessler P; Monia BP; Bitoun M; Ochala J; Laporte J; Cowling BS
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11066-11071. PubMed ID: 30291191
[TBL] [Abstract][Full Text] [Related]
11. Muscle-specific function of the centronuclear myopathy and Charcot-Marie-Tooth neuropathy-associated dynamin 2 is required for proper lipid metabolism, mitochondria, muscle fibers, neuromuscular junctions and peripheral nerves.
Tinelli E; Pereira JA; Suter U
Hum Mol Genet; 2013 Nov; 22(21):4417-29. PubMed ID: 23813975
[TBL] [Abstract][Full Text] [Related]
12. [The dynamin-2-gene related centronuclear myopathy].
Bitoun M
Med Sci (Paris); 2023 Nov; 39 Hors série n° 1():6-10. PubMed ID: 37975763
[TBL] [Abstract][Full Text] [Related]
13. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations.
Hanisch F; Müller T; Dietz A; Bitoun M; Kress W; Weis J; Stoltenburg G; Zierz S
J Neurol; 2011 Jun; 258(6):1085-90. PubMed ID: 21221624
[TBL] [Abstract][Full Text] [Related]
14. Subtle central and peripheral nervous system abnormalities in a family with centronuclear myopathy and a novel dynamin 2 gene mutation.
Echaniz-Laguna A; Nicot AS; Carré S; Franques J; Tranchant C; Dondaine N; Biancalana V; Mandel JL; Laporte J
Neuromuscul Disord; 2007 Dec; 17(11-12):955-9. PubMed ID: 17825552
[TBL] [Abstract][Full Text] [Related]
15. Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis.
Bitoun M; Durieux AC; Prudhon B; Bevilacqua JA; Herledan A; Sakanyan V; Urtizberea A; Cartier L; Romero NB; Guicheney P
Hum Mutat; 2009 Oct; 30(10):1419-27. PubMed ID: 19623537
[TBL] [Abstract][Full Text] [Related]
16. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice.
Durieux AC; Vignaud A; Prudhon B; Viou MT; Beuvin M; Vassilopoulos S; Fraysse B; Ferry A; Lainé J; Romero NB; Guicheney P; Bitoun M
Hum Mol Genet; 2010 Dec; 19(24):4820-36. PubMed ID: 20858595
[TBL] [Abstract][Full Text] [Related]
17. A rare case of centronuclear myopathy with
Aghbolaghi AG; Lechpammer M
Autops Case Rep; 2017; 7(2):43-48. PubMed ID: 28740838
[TBL] [Abstract][Full Text] [Related]
18. Calcium homeostasis alterations in a mouse model of the Dynamin 2-related centronuclear myopathy.
Fraysse B; Guicheney P; Bitoun M
Biol Open; 2016 Nov; 5(11):1691-1696. PubMed ID: 27870637
[TBL] [Abstract][Full Text] [Related]
19. Mild functional differences of dynamin 2 mutations associated to centronuclear myopathy and Charcot-Marie Tooth peripheral neuropathy.
Koutsopoulos OS; Koch C; Tosch V; Böhm J; North KN; Laporte J
PLoS One; 2011; 6(11):e27498. PubMed ID: 22096584
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2.
Mori-Yoshimura M; Okuma A; Oya Y; Fujimura-Kiyono C; Nakajima H; Matsuura K; Takemura A; Malicdan MC; Hayashi YK; Nonaka I; Murata M; Nishino I
Clin Neurol Neurosurg; 2012 Jul; 114(6):678-83. PubMed ID: 22613877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
